Table 3.
Cytotoxic activities of the compounds against three human cancer lines.
| Compound | IC50 (μM) a | ||
|---|---|---|---|
| A549 | HCT-8 | HepG2 | |
| 1 | >80 | >80 | >80 |
| 2 | >80 | >80 | >80 |
| 3 | >80 | >80 | >80 |
| 4 | 13.82 ± 2.23 | 6.79 ± 1.14 | 7.92 ± 1.38 |
| 5 | >80 | >80 | >80 |
| 6 | 47.63 ± 4.51 | 55.84 ± 5.99 | 30.92 ± 2.36 |
| 7 | 34.34 ± 3.80 | 27.79 ± 3.42 | 32.54 ± 2.69 |
| Doxorubicin b | 0.28 ± 0.05 | 1.55 ± 0.45 | 0.65 ± 0.11 |
Values are the mean ± S.D. for three separate experiments; a Compound concentration required to inhibit cell growth by 50%. Cells were treated with test samples (1–80 μM) for 24 h; b Doxorubicin was used as positive control, and DMSO was negative control.